Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR2002 in patients with moderate to severe atopic dermatitis
NCT06175143Phase 1Not yet recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Dec 2023
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GR2002 in atopic dermatitis (AD) (4 arms), sponsored by Zhixiang Jintai. Primary endpoint: Adverse events (AEs) at 20 weeks. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
GR2002
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06175143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06175143.